Analysis of risk factors of cord blood transplantation for children

Authors

  • Gal Goldstein MD,

    Corresponding author
    1. Department of Pediatric Hemato-Oncology and Bone Marrow Transplantation, The Edmond and Lily Safra Children's Hospital, Ramat Gan, Israel
    • Correspondence to: Gal Goldstein, Department of Pediatric Hemato-Oncology and Bone Marrow Transplantation, The Edmond and Lily Safra Children's Hospital, Israel.

      E-mail: galgolds@gmail.com

    Search for more papers by this author
  • Bella Bielorai MD,

    1. Department of Pediatric Hemato-Oncology and Bone Marrow Transplantation, The Edmond and Lily Safra Children's Hospital, Ramat Gan, Israel
    Search for more papers by this author
  • Jerry Stein MD,

    1. Department of Pediatric Hematology Oncology and Stem Cell Transplantation, Schneider Children's Medical Center of Israel, Petach Tikva, Israel
    Search for more papers by this author
  • Polina Stepensky MD,

    1. Department of Pediatric Hemato-Oncology, Hadassah Medical Center, Jerusalem, Israel
    Search for more papers by this author
  • Ronit Elhasid MD,

    1. Department of Pediatric Hemato-Oncology, Tel Aviv Medical Center, Tel Aviv, Israel
    Search for more papers by this author
  • Irena Zaidman MD,

    1. Department of Pediatric Hemato-Oncology, Tel Aviv Medical Center, Tel Aviv, Israel
    Search for more papers by this author
  • Angela Chetrit MSc,

    1. Cancer and Radiation Epidemiology Unit, Gertner Institute for Epidemiology and Health Policy Research, Chaim Sheba Medical Center, Tel Hashomer, Ramat Gan, Israel
    Search for more papers by this author
  • Isaac Yaniv MD,

    1. Department of Pediatric Hematology Oncology and Stem Cell Transplantation, Schneider Children's Medical Center of Israel, Petach Tikva, Israel
    Search for more papers by this author
  • Arnon Nagler MD,

    1. Hematology Division, Chaim Sheba Medical Center, Ramat Gan, Israel
    2. Cord Blood Bank, Chaim Sheba Medical Center, Tel Hashomer, Ramat Gan, Israel
    Search for more papers by this author
  • Amos Toren MD, PhD

    1. Department of Pediatric Hemato-Oncology and Bone Marrow Transplantation, The Edmond and Lily Safra Children's Hospital, Ramat Gan, Israel
    Search for more papers by this author

  • Conflict of interest: Nothing to declare.

Abstract

Background

As cord blood (CB) is being used frequently as a source for heamtopoetic stem cell transplantation defining risk factors for transplantation outcome is an important issue.

Procedure

The data of all single unit CB transplantation preformed in Israel from 1992 to 2011 were collected. The risk factors for myeloid engraftment, event free survival (EFS) and overall survival (OS) were studied in 87 children.

Results

There were 49 children with hematological malignancies and 38 with non-malignant diseases. Cumulative rate of neutrophil recovery was 78.3%, while median time to myeloid recovery was 26 days. The incidence of platelet engraftment at 150 days was 53%, and the median time to platelet recovery was 36 days. ABO blood group matching between CB unit and recipient was associated with superior myeloid engraftment. Acute graft versus host disease of grades II–IV occurred in 33% of the patients. Chronic graft versus host disease occurred in 16% of patients. Probabilities of EFS and OS at 1 year were 45% and 57%, respectively. Factors associated with inferior OS were Rh major mismatch versus matched Rh and transplantation from unrelated donor versus related donor.

Conclusions

These results indicate that matching of ABO blood groups is an important factor that affects engraftment, and also that Rh matching seem to have an impact on OS, which was not previously described in the setting of CB transplantation. Pediatr Blood Cancer 2013;60:2007–2011. © 2013 Wiley Periodicals, Inc.

Ancillary